Among patients with cancer who develop COVID-19, progressive disease and a higher ECOG* performance status (PS) are tied to an increased risk of mortality, according to early results ascertained from the COVID-19 and Cancer Consortium (CCC19) registry.
Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.
The addition of enzalutamide to androgen deprivation therapy (ADT) improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), demonstrated the phase III PROSPER* trial.
Prior treatment with chemotherapy alone, chemotherapy plus immunotherapy, steroids or anticoagulants is associated with an increased risk of death in patients with thoracic cancer who develop coronavirus disease 2019 (COVID-19), new data from the global TERAVOLT (Thoracic Cancers International COVID-10 Collaboration) registry have shown.
Vitamin D supplementation can reduce the incidence of advanced cancer among older adults, in particular those with a normal BMI but not those who are overweight or obese, suggests the large VITAL* randomized study presented during the ASCO 2020 Meeting.
Adding the PD-L1 inhibitor avelumab to best supportive care in the maintenance setting yields significant survival benefit compared with best supporting care alone for patients with advanced bladder cancer who have stable disease following first-line platinum-based chemotherapy, an interim analysis of the JAVELIN Bladder 100 study shows.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.
Three years of adjuvant imatinib treatment is superior in efficacy vs 1-year use in patients with gastrointestinal stromal tumours (GIST) at high risk of recurrence post-surgery, according to the secondary analysis of the SSGXVIII/AIO* trial.
The combination therapy of pembrolizumab + axitinib continued to demonstrate significant improvements in overall survival (OS) and progression-free survival (PFS) among patients with advanced renal cell carcinoma (RCC) over an extended 24-month follow-up, according to the KEYNOTE-426* study presented at ASCO20 Virtual Scientific Program.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.